This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eisai Co., Ltd.
Drug Names(s): polifeprosan 20 with carmustine, BCNU
Description: The Gliadel Wafer is a small wafer that contains the chemotherapeutic drug carmustine, or BCNU. After a specific brain tumor called a high-grade malignant glioma is surgically removed, up to 8 Gliadel Wafers are implanted in the cavity the tumor once occupied, slowly delivering carmustine directly to the tumor site. Carmustine, like other alkylating agents in the nitrosourea family, alkylates DNA causing inter- and intra-strand cross-linking.
As of 2015, BioMedTracker no longer forecasts revenues for Gliadel Wafer.
Gliadel Wafer was developed by Nova Pharmaceuticals. In 1990, Nova signed an agreement with Orion Corporation Farmos to develop and market Nova's Gliadel implant in Scandinavia. In 1992, Nova merged with Scios Pharmaceuticals to form Scios Nova. In October 1993, Guilford Pharmaceuticals was formed jointly by Scios Nova and two doctors.
On June 14, 1996, Rhone-Poulenc Rorer (now sanofi-aventis) and Guilford entered into a strategic agreement to develop oncology products using Guilford's proprietary biodegradable polymer implant technology. This agreement gives RPR the rights to market Gliadel Wafer worldwide, except in the Scandinavian countries.
In October 2000, Guilford reacquired commercial rights to Gliadel Wafer, from Aventis (now sanofi-aventis). Under the agreement with Aventis, Guilford reacquired worldwide marketing and distribution rights to Gliadel Wafer (except in Scandinavia,...See full deal structure in Biomedtracker
Partners: Orion Corporation Nobelpharma Co., Ltd. Arbor Pharmaceuticals, Inc.
Gliadel Wafer News
Pink Sheet Guilford Gliadel Wafer review rescheduled
Pink Sheet Gliadel Wafer advisory committee
Additional information available to subscribers only: